NASDAQ$BRKR

Bruker Corp · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Bruker's Q1 2022 performance was marked by solid revenue growth and operating improvements amidst supply chain challenges.

Bruker Corporation reported a 7.3% increase in revenue for Q1 2022, reaching $595.0 million, with organic revenue growth of 10.5%. The company's GAAP EPS was $0.41, and non-GAAP EPS was $0.49, a rise of 11.4% year-over-year. Due to strong demand, Bruker is raising its fiscal year 2022 organic revenue outlook.

  • Q1 2022 revenue increased by 7.3% year-over-year, with organic revenue growth of 10.5%.
  • GAAP EPS for Q1 2022 was $0.41, while non-GAAP EPS reached $0.49, up 11.4% year-over-year.
  • The company is raising its fiscal year 2022 organic revenue outlook due to strong demand.
  • Several key acquisitions and equity investments were made in proteomics, spatial biology, biopharma, applied markets and cancer biomarker companies.

Headline financials

Total Revenue

$595M

Previous: $555M+7.3%
EPS (adj)

$0.49

Previous: $0.44+11.4%
Organic Revenue Growth

10.5%

Previous: 23.8%-55.9%
Non-GAAP Operating Margin

19.5%

Previous: 18.4%+6.0%
GAAP Operating Margin

16.2%

Previous: 16.1%+0.6%
Capital Expenditures

-$19M

Previous: -$24.7M+23.1%
Free Cash Flow

$42.6M

Previous: $32M+33.1%
Net Income

$61.6M

Previous: $56.7M+8.6%
Operating Income

$96.5M

Previous: $89.1M+8.3%
Gross Profit

$306M

Previous: $279M+9.9%
Cash & Equivalents

$816M

Previous: $697M+17.1%
Total Assets

$3.55B

Previous: $3.03B+17.0%
Stock-Based Comp

$8M

Previous: $3.8M+110.5%

Revenue & EPS history

Bruker · Revenue · Quarterly

$595M

Q1 2022+7.3%vs Q1 2021
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Bruker · $59.7M total across 1 segment · Q1 2022

  • BEST
    $59.7M+13.9%

Forward guidance

Bruker is increasing its FY 2022 organic revenue growth guidance to reflect strong demand for its high-performance life science tools, scientific instruments, and diagnostic solutions. For FY 2022, Bruker expects 5% to 7% year-over-year reported revenue growth, including organic growth of 7% to 9%. Bruker continues to expect FY 2022 non-GAAP EPS of $2.29 to $2.33, a 9% to 11% increase year-over-year.

Tailwinds

  • Organic growth of 7% to 9%, an increase of 1% compared to prior guidance
  • M&A contributions of approximately 1.5%, an increase of 0.5% from prior guidance
  • Non-GAAP operating margin expansion of 30 bps to 60 bps from 19.4% in FY 2021
  • FY 2022 non-GAAP EPS of $2.29 to $2.33, a 9% to 11% increase year-over-year
  • Strong demand for high-performance life science tools

Headwinds

  • Foreign currency translation headwinds of approximately -3.5%, vs. prior guidance of -2%
  • Unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort.
  • Expected non-GAAP organic revenue, operating margin, tax rate and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments.
  • Reconciling items are uncertain and depend on various factors outside of management's control.
  • These items could significantly impact, either individually or in the aggregate, future period operating margins, EPS and tax rate calculated and presented in accordance with GAAP.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+0.8%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+3.3%

Avg return

30 days after

54%

35 / 65 earnings

Positive

+14.1%

Q1 2019

Best reaction

-13.1%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+11.2%+13.8%+48.3%
Q4 2025-11.6%-10.2%-20.5%
Q3 2025+6.4%+2.5%+22.9%
Q1 2025+3.4%+2.1%-2.9%
Q4 2024-1.0%-1.7%-11.0%
Q3 2024-0.6%-2.7%-1.5%
Q2 2024-5.1%-2.4%+2.8%
Q1 2024-11.4%-5.9%-17.1%
Q4 2023+13.4%+15.9%+30.1%
Q3 2023+3.2%+2.2%+15.9%
Q2 2023-6.7%-7.6%-7.1%
Q1 2023-2.1%-4.9%-11.0%
Q4 2022+5.2%+7.3%+1.0%
Q3 2022+9.5%+8.7%+9.6%
Q2 2022-7.4%-9.3%-18.2%
Q1 2022+1.2%-4.0%+5.3%
Q4 2021-7.7%-3.9%-12.1%
Q3 2021+1.7%+1.7%+0.9%
Q2 2021-1.8%+0.4%+8.7%
Q1 2021-0.5%-0.0%+1.4%
Q4 2020+1.1%+3.5%-1.1%
Q3 2020+3.4%+9.2%+21.6%
Q2 2020+0.2%-1.1%-4.1%
Q1 2020+6.2%+4.3%+16.9%
Q4 2019-4.0%-21.4%-8.1%
Q3 2019+12.4%+6.8%+14.9%
Q2 2019-13.1%-12.7%-9.8%
Q1 2019+14.1%+11.3%+9.6%
Q4 2018+6.3%+7.4%+8.5%
Q3 2018+6.6%+6.9%+5.8%
Q2 2018+7.4%+7.0%+9.1%
Q1 2018+2.0%+2.9%+3.4%
Q4 2017-7.8%-5.9%-6.8%
Q3 2017+4.5%+2.8%+9.2%
Q2 2017-1.2%-3.1%+3.2%
Q1 2017+3.8%+4.7%+12.1%
Q4 2016-1.8%-1.2%-3.1%
Q3 2016+3.6%+8.9%+10.1%
Q2 2016-12.2%-10.6%-9.6%
Q1 2016-3.1%
Q4 2015+9.5%
Q3 2015+7.8%
Q2 2015-5.4%
Q1 2015+10.6%
Q4 2014-2.1%
Q3 2014-12.5%
Q2 2014-9.4%
Q1 2014-0.8%
Q4 2013+2.0%
Q3 2013-7.1%
Q2 2013+11.1%
Q1 2013-4.3%
Q4 2012+8.3%
Q3 2012+4.1%
Q2 2012-1.6%
Q1 2012+7.4%
Q4 2011-0.9%
Q4 2009-0.9%
Q3 2010-4.0%
Q3 2011-4.0%
Q2 2010+4.0%
Q2 2011+4.0%
Q1 2010+1.9%
Q4 2010+1.9%
Q1 2011+1.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro